Meta‐analysis of high‐clearance anti‐amyloid immunotherapies trials in early Alzheimer’s disease: A significant clinical effect but a low benefit/risk ratio
Nicolas Villain,Vincent Planche
DOI: https://doi.org/10.1002/alz.064799
2023-06-01
Abstract:In the last three years, three over four phase II or III clinical trials using high‐dose anti‐amyloid immunotherapies in early Alzheimer’s disease (AD) have turned out to be positive on clinical outcomes: aducanumab (one of two), donanemab, and lecanemab. These results contrast with the previous failures of anti‐amyloid immunotherapies. Despite different pharmacodynamic properties, these drugs share a new characteristic: the high clearance of amyloid load as measured with amyloid positron emission tomography. In the meantime, the Food and Drug Administration’s conditional approval of aducanumab has led to unprecedented scientific controversies. We used the data from the highest dose group (i.e., the groups used for approval application or ongoing phase III trials) versus placebo after 18 months of the lecanemab and donanemab phase II trials and of the two aducanumab phase III trials to perform a meta‐analysis. Regarding clinical efficacy, we analyzed the CDR‐SB, ADASCog, and MMSE data. Regarding safety, we analyzed the occurrence of any Amyloid‐Related Imaging Abnormalities (ARIA), of ARIA‐edema (ARIA‐E), of ARIA‐hemorrhage (ARIA‐H), and of symptomatic and serious ARIA. The analyses were performed using RevMan 5.4.1 and a random effect model. High‐clearance anti‐amyloid immunotherapies were shown to significantly slow down cognitive decline after 18 months as measured with CDR‐SB (weighted mean = ‐0.24 points; p = 0.04), and ADAS‐Cog (weighted mean = ‐1.25 points; p = 0.0003), but not with MMSE (weighted mean = +0.31 points; p = 0.23) when compared to placebo. In parallel, the drugs significantly increased the occurrence of any ARIA (risk ratio = 3.68; p<0.0001), of ARIA‐E (risk ratio = 13.39; p<0.0001), of ARIA‐H (risk ratio = 2.78; p = 0.0002), and of symptomatic and serious ARIA (7/1321 = 0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio = 6.44; p = 0.04). When pooled together, the data from high‐clearance anti‐amyloid immunotherapies trials confirm a significant clinical effect after 18 months. However, this effect remains below the established minimal clinically relevant values. Safety remains an issue with 0.5% of symptomatic and serious ARIA, significantly beyond chance, despite thorough in‐trial monitoring and management. The benefit/risk ratio of this class of drugs in early AD is thus questionable after 18‐months. Identifying subgroups of better responders and the perspective of combination therapies may help improve their clinical relevance.
clinical neurology